DelistingJun 25, 2026, 05:02 PM
Heron Therapeutics Receives Nasdaq Delisting Warning
AI Summary
Heron Therapeutics received a notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement for continued listing. The company's common shares traded below $1.00 for 30 consecutive days between May 12 and June 24, 2026. Heron has 180 calendar days, until December 22, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive days. The notice does not immediately affect the trading of its shares, and the company plans to explore options to cure the deficiency.
Key Highlights
- Received Nasdaq notice for failing minimum $1.00 bid price requirement.
- Common shares traded below $1.00 for 30 consecutive days.
- Compliance period is 180 calendar days, until December 22, 2026.
- Must maintain $1.00 closing bid price for 10 consecutive days to regain compliance.
- No immediate impact on listing or trading of HRTX shares.
- May be eligible for an additional 180-day compliance period.
Price Impact
More from HRTX